340 related articles for article (PubMed ID: 33050486)
1. Lymphocyte Landscape after Chronic
Ghosh A; Romani S; Kottilil S; Poonia B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050486
[TBL] [Abstract][Full Text] [Related]
2. Peripheral PD-1
Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
Front Immunol; 2019; 10():1470. PubMed ID: 31316516
[TBL] [Abstract][Full Text] [Related]
3. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
5. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming.
Ellwanger JH; Kaminski VL; Valverde-Villegas JM; Simon D; Lunge VR; Chies JAB
Infect Genet Evol; 2018 Dec; 66():376-391. PubMed ID: 28811194
[TBL] [Abstract][Full Text] [Related]
6. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
8. Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy.
González-Aldaco K; Torres-Reyes LA; Ojeda-Granados C; José-Ábrego A; Fierro NA; Román S
Ann Hepatol; 2018 Oct; 17(6):908-919. PubMed ID: 30600305
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.
Zeng H; Li L; Hou Z; Zhang Y; Tang Z; Liu S
Int J Med Sci; 2020; 17(7):892-902. PubMed ID: 32308542
[TBL] [Abstract][Full Text] [Related]
11. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.
Shin EC; Han JW; Kang W; Kato T; Kim SJ; Zhong J; Kim S; Park SH; Sung PS; Watashi K; Park JY; Windisch MP; Oh JW; Wakita T; Han KH; Jang SK
Viruses; 2020 Mar; 12(3):. PubMed ID: 32168867
[No Abstract] [Full Text] [Related]
12. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.
Zhang C; Hua R; Cui Y; Wang S; Yan H; Li D; Zhang Y; Tu Z; Hao P; Chen X; Zhong J; Niu J; Jin X
PLoS One; 2017; 12(2):e0171217. PubMed ID: 28170421
[TBL] [Abstract][Full Text] [Related]
14. Adaptive Immune Response against Hepatitis C Virus.
Kemming J; Thimme R; Neumann-Haefelin C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781731
[TBL] [Abstract][Full Text] [Related]
15. T-cell therapy for chronic viral hepatitis.
Bertoletti A; Tan AT; Koh S
Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
[TBL] [Abstract][Full Text] [Related]
16. Pushing to a cure by harnessing innate immunity against hepatitis C virus.
Ireton RC; Gale M
Antiviral Res; 2014 Aug; 108():156-64. PubMed ID: 24907428
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence.
Quarleri JF; Oubiña JR
Ann Hepatol; 2016; 15(1):17-26. PubMed ID: 26626636
[TBL] [Abstract][Full Text] [Related]
18. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
19. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy.
Jackowiak P; Figlerowicz M; Kurzyńska-Kokorniak A; Figlerowicz M
Curr Pharm Biotechnol; 2011 Nov; 12(11):1774-80. PubMed ID: 21902631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
